Non-cigarette tobacco products: What have we learnt and where are we headed?

Tobacco Control

Volumn 21, Issue 2, 2012, Pages 181-190

  O'Connor, Richard J ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINE GUM;

ARTICLE; HARM REDUCTION; HUMAN; LEGAL ASPECT; MARKETING; METHODOLOGY; PUBLIC HEALTH SERVICE; SMOKELESS TOBACCO; SMOKING; SMOKING CESSATION; TOBACCO INDUSTRY;

HARM REDUCTION; HUMANS; MARKETING; PUBLIC HEALTH ADMINISTRATION; SMOKING; SMOKING CESSATION; TOBACCO INDUSTRY; TOBACCO USE CESSATION PRODUCTS; TOBACCO, SMOKELESS;

EID: 84857311630     PISSN: 09644563     EISSN: 14683318     Source Type: Journal    
DOI: 10.1136/tobaccocontrol-2011-050281     Document Type: Article

References (207)

1. Tobacco Free Initiative. Tobacco: Deadly in Any Form or Disguise. Geneva: World Health Organization, 2006. http://www.who.int/tobacco/communications/events/wntd/2006/Tfi_Rapport.pdf (accessed 25 Mar 2011).
2. Prignot JJ, Sasco AJ, Poulet E, et al. Alternative forms of tobacco use. Int J Tuberc Lung Dis 2008;12:718-27.
3. Le Houezec J, McNeill A, Britton J. Tobacco, nicotine and harm reduction. Drug Alcohol Rev 2011;30:119-23.
4. Cummings KM, Hyland A, Giovino GA, et al. Are smokers adequately informed about the health risks of smoking and medicinal nicotine? Nicotine Tob Res 2004;6 (Suppl 3):S333-40.
5. Smith SY, Curbow B, Stillman FA. Harm perception of nicotine products in college freshmen. Nicotine Tob Res 2007;9:977-82.
6. Shiffman S, Ferguson SG, Rohay J, et al. Perceived safety and efficacy of nicotine replacement therapies among US smokers and ex-smokers: relationship with use and compliance. Addiction 2008;103:1371-8.
7. Bansal MA, Cummings KM, Hyland A, et al. Stop-smoking medications: who uses them, who misuses them, and who is misinformed about them? Nicotine Tob Res 2004;6(Suppl 3):S303-10.
8. O'Connor RJ, McNeill A, Borland R, et al. Smokers' beliefs about the relative safety of other tobacco products: findings from the ITC collaboration. Nicotine Tob Res 2007;9:1033-42.
9. National Cancer Institute. Cigars: Health Effects and Trends. Smoking and Tobacco Control Monograph 9. Bethesda: National Cancer Institute, 1998.
10. Kozlowski LT, Dollar KM, Giovino GA. Cigar/cigarillo surveillance: limitations of the U.S. Department of Agriculture system. Am J Prev Med 2008;34:424-6.
11. Delnevo CD, Hrywna M. "A whole'nother smoke" or a cigarette in disguise: how RJ Reynolds reframed the image of little cigars. Am J Public Health 2007;97:1368-75.
12. Centers for Disease Control and Prevention (CDC). Cigar smoking among teenagersdUnited States, Massachusetts, and New York, 1996. MMWR Morb Mortal Wkly Rep 1997;46:433-40.
13. Nyman AL, Taylor TM, Biener L. Trends in cigar smoking and perceptions of health risks among Massachusetts adults. Tob Control 2002;11(Suppl 2):ii25-8.
14. Gilpin EA, Pierce JP. Cigar smoking in California: 1990-1996. Am J Prev Med 1999;16:195-201.
15. Delnevo CD. Smokers' choice: what explains the steady growth of cigar use in the U.S.? Public Health Rep 2006;121:116-19.
16. Soldz S, Huyser DJ, Dorsey E. The cigar as a drug delivery device: youth use of blunts. Addiction 2003;98:1379-86.
17. Baker F, Dye JT, Denniston MM, et al. Risk perception and cigar smoking behavior. Am J Health Behav 2001;25:106-14.
18. Delnevo CD, Hrywna M. The relationship of cigars, marijuana, and blunts to adolescent bidi use. Public Health Rep 2006;121:603-8.
19. Sifaneck SJ, Johnson BD, Dunlap E. Cigars-for-blunts: choice of tobacco products by blunt smokers. J Ethn Subst Abuse 2005;4:23-42.
20. Golub A, Johnson BD, Dunlap E. The growth in marijuana use among American youths during the 1990s and the extent of blunt smoking. J Ethn Subst Abuse 2005;4:1-21.
21. Rickert WS, Robinson JC, Bray DF, et al. Characterization of tobacco products: a comparative study of the tar, nicotine, and carbon monoxide yields of cigars, manufactured cigarettes, and cigarettes made from fine-cut tobacco. Prev Med 1985;14:226-33.
22. Appel BR, Guirguis G, Kim IS, et al. Benzene, benzo(a)pyrene, and lead in smoke from tobacco products other than cigarettes. Am J Public Health 1990;80:560-4.
23. Hoffmann D, Wynder EL. Smoke of cigarettes and little cigars: an analytical comparison. Science 1972;178:1197-9.
24. Rickert WS, Wright WG, Trivedi AH, et al. A comparative study of the mutagenicity of various types of tobacco products. Regul Toxicol Pharmacol 2007;48:320-30.
25. Henningfield JE, Fant RV, Radzius A, et al. Nicotine concentration, smoke pH and whole tobacco aqueous pH of some cigar brands and types popular in the United States. Nicotine Tob Res 1999;1:163-8.
26. Rodriguez J, Jiang R, Johnson WC, et al. The association of pipe and cigar use with cotinine levels, lung function, and airflow obstruction: a cross-sectional study. Ann Intern Med 2010;152:201-10.
27. Funck-Brentano C, Raphaël M, Lafontaine M, et al. Effects of type of smoking (pipe, cigars or cigarettes) on biological indices of tobacco exposure and toxicity. Lung Cancer 2006;54:11-18.
28. Pechacek TF, Folsom AR, de Gaudermaris R, et al. Smoke exposure in pipe and cigar smokers. Serum thiocyanate measures. JAMA 1985;254:3330-2.
29. Turner JA, Sillett RW, McNicol MW. Effect of cigar smoking on carboxyhaemoglobin and plasma nicotine concentrations in primary pipe and cigar smokers and ex-cigarette smokers. Br Med J 1977;2:1387-9.
30. Turner JA, Sillett RW, McNicol MW. The inhaling habits of pipe smokers. Br J Dis Chest 1981;75:71-6.
31. Goldman AL. Carboxyhemoglobin levels in primary and secondary cigar and pipe smokers. Chest 1977;72:33-5.
32. Baker F, Ainsworth SR, Dye JT, et al. Health risks associated with cigar smoking. JAMA 2000;284:735-40.
33. Wald NJ, Watt HC. Prospective study of effect of switching from cigarettes to pipes or cigars on mortality from three smoking related diseases. BMJ 1997;314:1860-3.
34. McCormack VA, Agudo A, Dahm CC, et al. Cigar and pipe smoking and cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). Int J Cancer 2010;127:2402-11.
35. Boffetta P, Pershagen G, Jöckel KH, et al. Cigar and pipe smoking and lung cancer risk: a multicenter study from Europe. J Natl Cancer Inst 1999;91:697-701.
36. Shapiro JA, Jacobs EJ, Thun MJ. Cigar smoking in men and risk of death from tobacco-related cancers. J Natl Cancer Inst 2000;92:333-7.
37. Iribarren C, Tekawa IS, Sidney S, et al. Effect of cigar smoking on the risk of cardiovascular disease, chronic obstructive pulmonary disease, and cancer in men. N Engl J Med 1999;340:1773-80.
38. Tverdal A, Bjartveit K. Health consequences of pipe versus cigarette smoking. Tob Control 2011;20:123-30.
39. Henley SJ, Thun MJ, Chao A, et al. Association between exclusive pipe smoking and mortality from cancer and other diseases. J Natl Cancer Inst 2004;96:853-61.
40. Shaper AG, Wannamethee SG, Walker M. Pipe and cigar smoking and major cardiovascular events, cancer incidence and all-cause mortality in middle-aged British men. Int J Epidemiol 2003;32:802-8.
41. Bertuccio P, La Vecchia C, Silverman DT, et al. Cigar and pipe smoking, smokeless tobacco use and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (PanC4). Ann Oncol 2011;22:1420-6.
42. Hrywna M, Delnevo CD, Pevzner ES, et al. Correlates of bidi use among youth. Am J Health Behav 2004;28:173-9.
43. Guidotti TL, Laing L, Prakash UB. Clove cigarettes. The basis for concern regarding health effects. West J Med 1989;151:220-8.
44. Guidotti TL, Laing L. Clove cigarettes. West J Med 1992;156:537-8.
45. American Medical Association Council on Scientific Affairs. Evaluation of the health hazard of clove cigarettes. JAMA 1988;260:3641-4.
46. Polzin GM, Stanfill SB, Brown CR, et al. Determination of eugenol, anethole, and coumarin in the mainstream cigarette smoke of Indonesian clove cigarettes. Food Chem Toxicol 2007;45:1948-53.
47. Stanfill SB, Brown CR, Yan XJ, et al. Quantification of flavor-related compounds in the unburned contents of bidi and clove cigarettes. J Agric Food Chem 2006;54:8580-8.
48. Stanfill SB, Calafat AM, Brown CR, et al. Concentrations of nine alkenylbenzenes, coumarin, piperonal and pulegone in Indian bidi cigarette tobacco. Food Chem Toxicol 2003;41:303-17.
49. Watson CH, Polzin GM, Calafat AM, et al. Determination of tar, nicotine, and carbon monoxide yields in the smoke of bidi cigarettes. Nicotine Tob Res 2003;5:747-53.
50. Wu W, Song S, Ashley DL, et al. Assessment of tobacco-specific nitrosamines in the tobacco and mainstream smoke of bidi cigarettes. Carcinogenesis 2004;25:283-7.
51. Malson JL, Lee EM, Murty R, et al. Clove cigarette smoking: biochemical, physiological, and subjective effects. Pharmacol Biochem Behav 2003;74:739-45.
52. Kumar R, Prakash S, Kushwah AS, et al. Breath carbon monoxide concentration in cigarette and bidi smokers in India. Indian J Chest Dis Allied Sci 2010;52:19-24.
53. Behera D, Dash S, Dinakar M. Correlation of smoking behaviour and blood carboxyhaemoglobin in bidi and cigarette smokers. Indian J Chest Dis Allied Sci 1991;33:43-6.
54. Gupta PC, Asma S, eds. Bidi Smoking and Public Health. New Delhi: Ministry of Health and Family Welfare, Government of India, 2008.
55. Pednekar MS, Gupta PC, Yeole BB, et al. Association of tobacco habits, including bidi smoking, with overall and site-specific cancer incidence: results from the Mumbai cohort study. Cancer Causes Control 2011;22:859-68.
56. Prasad R, Ahuja RC, Singhal S, et al. A case-control study of bidi smoking and bronchogenic carcinoma. Ann Thorac Med 2010;5:238-41.
57. Prasad R, Singhal S, Garg R. Bidi smoking and lung cancer. Biosci Trends 2009;3:41-3.
58. Jayalekshmy PA, Akiba S, Nair MK, et al. Bidi smoking and lung cancer incidence among males in Karunagappally cohort in Kerala, India. Int J Cancer 2008;123:1390-7.
59. Gajalakshmi V, Peto R, Kanaka TS, et al. Smoking and mortality from tuberculosis and other diseases in India: retrospective study of 43000 adult male deaths and 35000 controls. Lancet 2003;362:507-15.
60. Pednekar MS, Gupta PC. Prospective study of smoking and tuberculosis in India. Prev Med 2007;44:496-8.
61. Suryanto E. Merokok & Kanker Paru [Smoking and Lung Cancer] (In Indonesian). Thesis. Jakarta, Indonesia: Department of Pulmonology, Faculty of Medicine, University of Indonesia, 1988.
62. Situmeang T. Hubungan Merokok Krete Dengan Kanker Paru [The Relation Between Kretek Cigarette and Lung Cancer] (In Indonesian). Thesis. Jakarta, Indonesia: Department of Pulmonology, Faculty of Medicine, University of Indonesia, 2000.
63. Study Group on Tobacco Product Regulation. Waterpipe Tobacco Smoking: Health Effects, Research Needs and Recommended Actions by Regulators. Geneva: World Health Organization, 2005.
64. Maziak W. The global epidemic of waterpipe smoking. Addict Behav 2011;36:1-5.
65. Maziak W. The waterpipe: time for action. Addiction 2008;103:1763-7.
66. Maziak W, Ward KD, Afifi Soweid RA, et al. Tobacco smoking using a waterpipe: a re-emerging strain in a global epidemic. Tob Control 2004;13:327-33.
67. Rastam S, Ward KD, Eissenberg T, et al. Estimating the beginning of the waterpipe epidemic in Syria. BMC Public Health 2004;4:32.
68. Eissenberg T, Ward KD, Smith-Simone S, et al. Waterpipe tobacco smoking on a U.S. College campus: prevalence and correlates. J Adolesc Health 2008;42:526-9.
69. Sutfin EL, McCoy TP, Reboussin BA, et al. Prevalence and correlates of waterpipe tobacco smoking by college students in North Carolina. Drug Alcohol Depend 2011;115:131-6.
70. Jackson D, Aveyard P. Waterpipe smoking in students: prevalence, risk factors, symptoms of addiction, and smoke intake. Evidence from one British university. BMC Public Health 2008;8:174.
71. Jawaid A, Zafar AM, Rehman TU, et al. Knowledge, attitudes and practice of university students regarding waterpipe smoking in Pakistan. Int J Tuberc Lung Dis 2008;12:1077-84.
72. Maziak W, Fouad FM, Asfar T, et al. Prevalence and characteristics of narghile smoking among university students in Syria. Int J Tuberc Lung Dis 2004;8:882-9.
73. Primack BA, Sidani J, Agarwal AA, et al. Prevalence of and associations with waterpipe tobacco smoking among U.S. university students. Ann Behav Med 2008;36:81-6.
74. Roskin J, Aveyard P. Canadian and English students' beliefs about waterpipe smoking: a qualitative study. BMC Public Health 2009;9:10.
75. Smith-Simone S, Maziak W, Ward KD, et al. Waterpipe tobacco smoking: knowledge, attitudes, beliefs, and behavior in two U.S. samples. Nicotine Tob Res 2008;10:393-8.
76. Asfar T, Ward KD, Eissenberg T, et al. Comparison of patterns of use, beliefs, and attitudes related to waterpipe between beginning and established smokers. BMC Public Health 2005;5:19.
77. Maziak W, Rastam S, Shihadeh AL, et al. Nicotine exposure in daily waterpipe smokers and its relation to puff topography. Addict Behav 2011;36:397-9.
78. Maziak W, Rastam S, Ibrahim I, et al. CO exposure, puff topography, and subjective effects in waterpipe tobacco smokers. Nicotine Tob Res 2009;11:806-11.
79. Blank MD, Cobb CO, Kilgalen B, et al. Acute effects of waterpipe tobacco smoking: a double-blind, placebo-control study. Drug Alcohol Depend 2011;116:102-9.
80. Bacha ZA, Salameh P, Waked M. Saliva cotinine and exhaled carbon monoxide levels in natural environment waterpipe smokers. Inhal Toxicol 2007;19:771-7.
81. Cobb CO, Shihadeh A, Weaver MF, et al. Waterpipe tobacco smoking and cigarette smoking: a direct comparison of toxicant exposure and subjective effects. Nicotine Tob Res 2011;13:78-87.
82. Neergaard J, Singh P, Job J, et al. Waterpipe smoking and nicotine exposure: a review of the current evidence. Nicotine Tob Res 2007;9:987-94.
83. Monzer B, Sepetdjian E, Saliba N, et al. Charcoal emissions as a source of CO and carcinogenic PAH in mainstream narghile waterpipe smoke. Food Chem Toxicol 2008;46:2991-5.
84. Sepetdjian E, Saliba N, Shihadeh A. Carcinogenic PAH in waterpipe charcoal products. Food Chem Toxicol 2010;48:3242-5.
85. England LJ, Kim SY, Tomar SL, et al. Non-cigarette tobacco use among women and adverse pregnancy outcomes. Acta Obstet Gynecol Scand 2010;89:454-64.
86. Akl EA, Gaddam S, Gunukula SK, et al. The effects of waterpipe tobacco smoking on health outcomes: a systematic review. Int J Epidemiol 2010;39:834-57.
87. Raad D, Gaddam S, Schunemann HJ, et al. Effects of waterpipe tobacco smoking on lung function: a systematic review and meta-analysis. Chest 2011;139:764-74.
88. International Agency for Research on Cancer. Smokeless Tobacco and Some Tobacco-Specific N-Nitrosamines. Monograph 89. Lyon: International Agency for Research on Cancer, 2007.
89. Stanfill SB, Connolly GN, Zhang L, et al. Global surveillance of oral tobacco products: total nicotine, unionised nicotine and tobacco-specific N-nitrosamines. Tob Control 2011;20:e2.
90. Richter P, Hodge K, Stanfill S, et al. Surveillance of moist snuff: total nicotine, moisture, pH, un-ionized nicotine, and tobacco-specific nitrosamines. Nicotine Tob Res 2008;10:1645-52.
91. Stepanov I, Jensen J, Hatsukami D, et al. New and traditional smokeless tobacco: comparison of toxicant and carcinogen levels. Nicotine Tob Res 2008;10:1773-82.
92. McNeill A, Bedi R, Islam S, et al. Levels of toxins in oral tobacco products in the UK. Tob Control 2006;15:64-7.
93. Stepanov I, Hecht SS, Ramakrishnan S, et al. Tobacco-specific nitrosamines in smokeless tobacco products marketed in India. Int J Cancer 2005;116:16-19.
94. Idris AM, Nair J, Ohshima H, et al. Unusually high levels of carcinogenic tobaccospecific nitrosamines in Sudan snuff (toombak). Carcinogenesis 1991;12:1115-18.
95. Luo J, Ye W, Zendehdel K, et al. Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort study. Lancet 2007;369:2015-e20.
96. Boffetta P, Aagnes B, Weiderpass E, et al. Smokeless tobacco use and risk of cancer of the pancreas and other organs. Int J Cancer 2005;114:992-5.
97. Boffetta P, Straif K. Use of smokeless tobacco and risk of myocardial infarction and stroke: systematic review with meta-analysis. BMJ 2009;339:b3060.
98. Critchley JA, Unal B. Is smokeless tobacco a risk factor for coronary heart disease? A systematic review of epidemiological studies. Eur J Cardiovasc Prev Rehabil 2004;11:101-12.
99. Critchley JA, Unal B. Health effects associated with smokeless tobacco: a systematic review. Thorax 2003;58:435-43.
100. Boffetta P, Hecht S, Gray N, et al. Smokeless tobacco and cancer (review). Lancet Oncol 2008;9:667-75.
101. Gupta PC, Ray CS. Smokeless tobacco and health in India and South Asia. Respirology 2003;8:419-31.
102. Sapkota A, Gajalakshmi V, Jetly DH, et al. Smokeless tobacco and increased risk of hypopharyngeal and laryngeal cancers: a multicentric case-control study from India. Int J Cancer 2007;121:1793-8.
103. Gupta PC, Murti PR, Bhonsle RB. Epidemiology of cancer by tobacco products and the significance of TSNA. Crit Rev Toxicol 1996;26:183-98.
104. Foulds J, Furberg H. Is low-nicotine Marlboro snus really snus? Harm Reduct J 2008;5:9.
105. Henningfield JE, Fagerstrom KO. Swedish Match Company, Swedish snus and public health: a harm reduction experiment in progress? Tob Control 2001;10:253-7.
106. Fagerström KO, Schildt EB. Should the European Union lift the ban on snus? Evidence from the Swedish experience. Addiction 2003;98:1191-5.
107. Foulds J, Ramstrom L, Burke M, et al. Effect of smokeless tobacco (snus) on smoking and public health in Sweden. Tob Control 2003;12:349-59.
108. Rodu B, Stegmayr B, Nasic S, et al. Evolving patterns of tobacco use in northern Sweden. J Intern Med 2003;253:660-5.
109. Rodu B, Cole P. The burden of mortality from smoking: comparing Sweden with other countries in the European Union. Eur J Epidemiol 2004;19:129-31.
110. Tomar SL, Connolly GN, Wilkenfeld J, et al. Declining smoking in Sweden: is Swedish Match getting the credit for Swedish tobacco control's efforts? Tob Control 2003;12:368-71.
111. Bolinder G. Swedish snuff: a hazardous experiment when interpreting scientific data into public health ethics. Addiction 2003;98:1201-4.
112. Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR). Health Effects of Smokeless Tobacco Products. Brussels: Health and Consumer Protection Directorate-General, European Commission, 2008.
113. Henley SJ, Connell CJ, Richter P, et al. Tobacco-related disease mortality among men who switched from cigarettes to spit tobacco. Tob Control 2007;16:22-8.
114. Bates C, Fagerström K, Jarvis MJ, et al. European Union policy on smokeless tobacco: a statement in favour of evidence based regulation for public health. Tob Control 2003;12:360-7.
115. Kozlowski LT. Effect of smokeless tobacco product marketing and use on population harm from tobacco use policy perspective for tobacco-risk reduction. Am J Prev Med 2007;33(6 Suppl):S379-86.
116. Hatsukami DK, Lemmonds C, Tomar SL. Smokeless tobacco use: harm reduction or induction approach? Prev Med 2004;38:309-17.
117. Tomar SL. Epidemiologic perspectives on smokeless tobacco marketing and population harm. Am J Prev Med 2007;33(6 Suppl):S387-97.
118. Phillips CV, Heavner KK. Smokeless tobacco: the epidemiology and politics of harm. Biomarkers 2009;14(Suppl 1):79-84.
119. Zeller M, Hatsukami D; Strategic Dialogue on Tobacco Harm Reduction Group. The strategic dialogue on tobacco harm reduction: a vision and blueprint for action in the US. Tob Control 2009;18:324-32.
120. Gartner CE, Hall WD, Chapman S, et al. Should the health community promote smokeless tobacco (snus) as a harm reduction measure? PLoS Med 2007;4:e185.
121. Tomar SL, Fox BJ, Severson HH. Is smokeless tobacco use an appropriate public health strategy for reducing societal harm from cigarette smoking? Int J Environ Res Public Health 2009;6:10-24.
122. Savitz DA, Meyer RE, Tanzer JM, et al. Public health implications of smokeless tobacco use as a harm reduction strategy. Am J Public Health 2006;96:1934-9.
123. Alderman J, Dollar KM, Kozlowski LT. Commentary: understanding the origins of anger, contempt, and disgust in public health policy disputes: applying moral psychology to harm reduction debates. J Public Health Policy 2010;31:1-16.
124. Henningfield JE, Rose CA, Giovino GA. Brave new world of tobacco disease prevention: promoting dual tobacco-product use? Am J Prev Med 2002;23:226-8.
125. Ramström LM, Foulds J. Role of snus in initiation and cessation of tobacco smoking in Sweden. Tob Control 2006;15:210-14.
126. Galanti MR, Rosendahl I, Wickholm S. The development of tobacco use in adolescence among "snus starters" and "cigarette starters": an analysis of the Swedish "BROMS" cohort. Nicotine Tob Res 2008;10:315-23.
127. Stenbeck M, Hagquist C, Rosén M. The association of snus and smoking behaviour: a cohort analysis of Swedish males in the 1990s. Addiction 2009;104:1579-85.
128. Tomar SL. Is use of smokeless tobacco a risk factor for cigarette smoking? The U.S. experience. Nicotine Tob Res 2003;5:561-9.
129. Severson HH, Forrester KK, Biglan A. Use of smokeless tobacco is a risk factor for cigarette smoking. Nicotine Tob Res 2007;9:1331-7.
130. Haddock CK, Weg MV, DeBon M, et al. Evidence that smokeless tobacco use is a gateway for smoking initiation in young adult males. Prev Med 2001;32:262-7.
131. Timberlake DS, Huh J, Lakon CM. Use of propensity score matching in evaluating smokeless tobacco as a gateway to smoking. Nicotine Tob Res 2009;11:455-62.
132. Kozlowski LT, O'Connor RJ, Edwards BQ, et al. Most smokeless tobacco use is not a causal gateway to cigarettes: using order of product use to evaluate causation in a national US sample. Addiction 2003;98:1077-85.
133. O'Connor RJ, Flaherty BP, Quinio Edwards B, et al. Regular smokeless tobacco use is not a reliable predictor of smoking onset when psychosocial predictors are included in the model. Nicotine Tob Res 2003;5:535-43.
134. Rodu B, Cole P. Evidence against a gateway from smokeless tobacco use to smoking. Nicotine Tob Res 2010;12:530-4.
135. McClave-Regan AK, Berkowitz J. Smokers who are also using smokeless tobacco products in the US: a national assessment of characteristics, behaviours and beliefs of 'dual users'. Tob Control 2011;20:239-42.
136. Tomar SL, Alpert HR, Connolly GN. Patterns of dual use of cigarettes and smokeless tobacco among US males: findings from national surveys. Tob Control 2010;19:104-9.
137. Mumford EA, Levy DT, Gitchell JG, et al. Tobacco control policies and the concurrent use of smokeless tobacco and cigarettes among men, 1992-2002. Nicotine Tob Res 2005;7:891-900.
138. Wetter DW, McClure JB, de Moor C, et al. Concomitant use of cigarettes and smokeless tobacco: prevalence, correlates, and predictors of tobacco cessation. Prev Med 2002;34:638-48.
139. Kozlowski LT, Strasser AA, Giovino GA, et al. Applying the risk/use equilibrium: use medicinal nicotine now for harm reduction. Tob Control 2001;10:201-3.
140. Levy DT, Mumford EA, Cummings KM, et al. The relative risks of a low-nitrosamine smokeless tobacco product compared with smoking cigarettes: estimates of a panel of experts. Cancer Epidemiol Biomarkers Prev 2004;13:2035-42.
141. Levy DT, Mumford EA, Cummings KM, et al. The potential impact of a low-nitrosamine smokeless tobacco product on cigarette smoking in the United States: estimates of a panel of experts. Addict Behav 2006;31:1190-200.
142. Gartner CE, Hall WD, Vos T, et al. Assessment of Swedish snus for tobacco harm reduction: an epidemiological modelling study. Lancet 2007;369:2010-14.
143. Mejia AB, Ling PM, Glantz SA. Quantifying the effects of promoting smokeless tobacco as a harm reduction strategy in the USA. Tob Control 2010;19:297-305.
144. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev 2008;(1):CD000146.
145. Beard E, McNeill A, Aveyard P, et al. Use of nicotine replacement therapy for smoking reduction and during enforced temporary abstinence: a national survey of English smokers. Addiction 2011;106:197-204.
146. Tobacco Free Initiative. Two forms of nicotine replacement therapy chosen as WHO "Essential Medicines". 2009. http://www.who.int/tobacco/communications/highlights/note_nrt_therapy/en/index.html
147. Gray N, Henningfield JE, Benowitz NL, et al. Toward a comprehensive long term nicotine policy. Tob Control 2005;14:161-5.
148. McNeill A, Foulds J, Bates C. Regulation of nicotine replacement therapies (NRT): a critique of current practice. Addiction 2001;96:1757-68.
149. Sweanor D. Regulatory imbalance between medicinal and non-medicinal nicotine. Addiction 2000;95(Suppl 1):S25-8.
150. Warner KE, Slade J, Sweanor DT. The emerging market for long-term nicotine maintenance. JAMA 1997;278:1087-92.
151. Hammond D, Reid JL, Driezen P, et al. Smokers' use of nicotine replacement therapy for reasons other than stopping smoking: findings from the ITC Four Country Survey. Addiction 2008;103:1696-703. Erratum in: Addiction 2008;103:2075.
152. Levy DE, Thorndike AN, Biener L, et al. Use of nicotine replacement therapy to reduce or delay smoking but not to quit: prevalence and association with subsequent cessation efforts. Tob Control 2007;16:384-9.
153. Gerlach KK, Rohay JM, Gitchell JG, et al. Use of nicotine replacement therapy among never smokers in the 1999-2006 National Health and Nutrition Examination Surveys. Drug Alcohol Depend 2008;98:154-8.
154. Rainio SU, Huhtala HS, Rimpelä AH. Use and acquisition of nicotine replacement therapy products among underaged adolescents after deregulation of the sales. Nicotine Tob Res 2010;12:870-3.
155. Horowitz DJ. Warning Letter to Bird's Hill Pharmacy Re: Nicotine Lollipops. Food and Drug Administration. 2002. http://www.fda.gov/foi/warning_letters/archive/g3226d.htm
156. Horowitz DJ. Warning Letter to The Compounding Pharmacy Re: Nicotine Lollipops and Lip Balm. Food and Drug Administration. 2002. http://www.fda.gov/foi/warning_letters/archive/g3225d.htm
157. Schultz WB, Angulo CT, Cabe ME, et al. Petition for Regulation of S&F Garrett's Nicotine Water. 2001. http://news.findlaw.com/hdocs/docs/tobacco/nich20fda121801pet.pdf
158. Pauly J, Li Q, Barry MB. Tobacco-free electronic cigarettes and cigars deliver nicotine and generate concern. Tob Control 2007;16:357.
159. Ayers JW, Ribisl KM, Brownstein JS. Tracking the rise in popularity of electronic nicotine delivery systems (electronic cigarettes) using search query surveillance. Am J Prev Med 2011;40:448-53.
160. Yamin CK, Bitton A, Bates DW. E-cigarettes: a rapidly growing Internet phenomenon. Ann Intern Med 2010;153:607-9.
161. Etter JF, Bullen C, Flouris AD, et al. Electronic nicotine delivery systems: a research agenda. Tob Control 2011;20:243-8.
162. Cahn Z, Siegel M. Electronic cigarettes as a harm reduction strategy for tobacco control: a step forward or a repeat of past mistakes? J Public Health Policy 2011;32:16-31.
163. Wollscheid KA, Kremzner ME. Electronic cigarettes: safety concerns and regulatory issues. Am J Health Syst Pharm 2009;66:1740-2.
164. Trtchounian A, Talbot P. Electronic nicotine delivery systems: is there a need for regulation? Tob Control 2011;20:47-52.
165. Vansickel AR, Cobb CO, Weaver MF, et al. A clinical laboratory model for evaluating the acute effects of electronic "cigarettes": nicotine delivery profile and cardiovascular and subjective effects. Cancer Epidemiol Biomarkers Prev 2010;19:1945-53.
166. Bullen C, McRobbie H, Thornley S, et al. Effect of an electronic nicotine delivery device (e cigarette) on desire to smoke and withdrawal, user preferences and nicotine delivery: randomised cross-over trial. Tob Control 2010;19:98-103.
167. Etter JF, Bullen C. Electronic cigarette: users profile, utilization, satisfaction and perceived efficacy. Addiction 2011;106:2017-28.
168. Siegel MB, Tanwar KL, Wood KS. Electronic cigarettes as a smoking-cessation tool results from an online survey. Am J Prev Med 2011;40:472-5.
169. Flouris AD, Oikonomou DN. Electronic cigarettes: miracle or menace? BMJ 2010;340:c311.
170. Timberlake DS, Pechmann C, Tran SY, et al. A content analysis of camel snus advertisements in print media. Nicotine Tob Res 2011;13:431-9.
171. Curry LE, Pederson LL, Stryker JE. The changing marketing of smokeless tobacco in magazine advertisements. Nicotine Tob Res 2011;13:540-7.
172. Mejia AB, Ling PM. Tobacco industry consumer research on smokeless tobacco users and product development. Am J Public Health 2010;100:78-87.
173. Noonan D. Exemptions for hookah bars in clean indoor air legislation: a public health concern. Public Health Nurs 2010;27:49-53.
174. Martinasek MP, McDermott RJ, Martini L. Waterpipe (hookah) tobacco smoking among youth. Curr Probl Pediatr Adolesc Health Care 2011;41:34-57.
175. Borland R, Wilson N, Fong GT, et al. Impact of graphic and text warnings on cigarette packs: findings from four countries over five years. Tob Control 2009;18:358-64.
176. Borland R, Yong HH, Wilson N, et al. How reactions to cigarette packet health warnings influence quitting: findings from the ITC Four-Country survey. Addiction 2009;104:669-75.
177. Hammond D, Fong GT, Borland R, et al. Text and graphic warnings on cigarette packages: findings from the international tobacco control four country study. Am J Prev Med 2007;32:202-9.
178. Callery WE, Hammond D, O'Connor RJ, et al. The appeal of smokeless tobacco products among young canadian smokers: the impact of pictorial health warnings and relative risk messages. Nicotine Tob Res 2011;13:373-83.
179. Conference of the Parties. Partial guidelines for implementation of Articles 9 and 10 of the WHO Framework Convention on Tobacco Control (Regulation of the contents of tobacco products and Regulation of tobacco product disclosures). 2010. http://www.who.int/fctc/guidelines/Decisions9and10.pdf
180. WHO Study Group on Tobacco Product Regulation. Report on the Scientific Basis of Tobacco Product Regulation: Third Report of a WHO Study Group. WHO Technical Report Series 955. Geneva: WHO, 2009.
181. Hecht SS, Stepanov I, Hatsukami DK. Major tobacco companies have technology to reduce carcinogen levels but do not apply it to popular smokeless tobacco products. Tob Control 2011;20:443.
182. Ayo-Yusuf OA, Connolly GN. Applying toxicological risk assessment principles to constituents of smokeless tobacco products: implications for product regulation. Tob Control 2011;20:53-7.
183. Associated Press. Importer Tries to Get Around Clove Cigarette Ban. MSNBC, 2009. http://www.msnbc.msn.com/id/32723154/ns/business-consumer_news/
184. Zajac A. FDA says tobacco law doesn't apply to two smokeless lozenges. Los Angeles Times 25 March 2011. http://articles.latimes.com/2011/mar/25/news/la-pn-tobacco-lozenges-fda-20110325
185. Food and Drug Administration. Clarification About Dissolvable Tobacco Products. http://www.fda.gov/TobaccoProducts/NewsEvents/ucm248801.htm
186. Deyton LR, Woodcock J. Regulation of E-Cigarettes and Other Tobacco Products. Food and Drug Administration, 2011. http://www.fda.gov/NewsEvents/PublicHealthFocus/ucm252360.htm
187. World Health Organization. WHO Technical Manual on Tobacco Tax Administration. Geneva: WHO, 2010.
188. Campaign for Tobacco-Free Kids. Closing weight-based tax loopholes for the new generation of low weight moist snuff smokeless tobacco products. 2011. http://www.tobaccofreekids.org/research/factsheets/pdf/0355.pdf
189. Licht AS, Hyland AJ, O'Connor RJ, et al. Socio-economic variation in price minimizing behaviors: findings from the International Tobacco Control (ITC) Four Country Survey. Int J Environ Res Public Health 2011;8:234-52.
190. Kesmodel D. Close, and it is a cigar. Wall St J 2010. http://online.wsj.com/article/SB10001424052748703399404575505670223138144.html
191. Apuzzo M. Tobacco executives find tax loophole in child health law. The Boston Globe 18 November 2009. http://www.boston.com/news/health/articles/2009/11/18/tobacco_executives_quickly_find_tax_loophole/
192. Campaign for Tobacco-Free Kids. Creating federal tax equity among all tobacco products would increase federal revenues and promote public health. 2010. http://www.tobaccofreekids.org/research/factsheets/pdf/0354.pdf
193. Carpenter CM, Connolly GN, Ayo-Yusuf OA, et al. Developing smokeless tobacco products for smokers: an examination of tobacco industry documents. Tob Control 2009;18:54-9.
194. Kozlowski LT. The determinants of tobacco use: cigarette smoking in the context of other forms of tobacco use. Can J Public Health 1982;73:236-41.
195. Slade J. The tobacco epidemic: lessons from history. J Psychoactive Drugs 1992;24:99-109.
196. Bell K, McCullough L, Salmon A, et al. 'Every space is claimed': smokers' experiences of tobacco denormalisation. Sociol Health Illn 2010;32:914-29.
197. Stuber J, Galea S, Link BG. Smoking and the emergence of a stigmatized social status. Soc Sci Med 2008;67:420-30.
198. Ritchie D, Amos A, Martin C. "But it just has that sort of feel about it, a leper"dstigma, smoke-free legislation and public health. Nicotine Tob Res 2010;12:622-9.
199. Chapman S, Freeman B. Markers of the denormalisation of smoking and the tobacco industry. Tob Control 2008;17:25-31.
200. Noel JK, Rees VW, Connolly GN. Electronic cigarettes: a new 'tobacco' industry? Tob Control 2011;20:81.
201. Freeman B, Chapman S. Gone viral? Heard the buzz? A guide for public health practitioners and researchers on how Web 2.0 can subvert advertising restrictions and spread health information. J Epidemiol Community Health 2008;62:778-82.
202. Rogers EM. Diffusion of Innovations. 5th edn. New York: Free Press, 2003.
203. Anderson SJ, Ling PM. "And they told two friends. and so on": RJ Reynolds' viral marketing of Eclipse and its potential to mislead the public. Tob Control 2008;17:222-9.
204. Freeman B, Chapman S. British American Tobacco on Facebook: undermining Article 13 of the global World Health Organization Framework Convention on Tobacco Control. Tob Control 2010;19:e1-9.
205. Elkin L, Thomson G, Wilson N. Connecting world youth with tobacco brands: YouTube and the internet policy vacuum on Web 2.0 Tob Control 2010;19:361-6.
206. Wackowski OA, Lewis MJ, Delnevo CD. Qualitative analysis of Camel Snus' website message boarddusers' product perceptions, insights and online interactions. Tob Control 2011;20:e1.
207. Young D, Borland R. Conceptual challenges in the translation of research into practice: it's not just a matter of "communication". Translational Behavioral Medicine 2011;1:256-69.